GMA161

Phase 1Biologic

Sanofi

GMA161 is one of 25 biologic programs targeting Thrombocytopenic Purpura. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thrombocytopenic PurpuraActive, not recruiting

Thrombocytopenic PurpuraPhase 1

Active, not recruiting

Competition

Competitive Landscape

47 competitors in Thrombocytopenic Purpura

#DrugCompanyPhaseTrials

Promacta

GSK

Phase 3

11 2

Rayos

RRoxane Laboratories

Phase 3

4 3

Decadron

AAspen Global Incorporated

Phase 3

3 4

Doptelet

AAkarx

Phase 3

2 5

Igpro10

CSL Behring

Approved

1 6

Rituxan

Roche

Phase 2

6 7

AMG 531

Amgen

Phase 3

3 8

Fostamatinib Bid

RRigel Pharmaceuticals

Phase 3

4 9

Immunoglobulin

Sanofi

Phase 2

2 10

Doxil

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thrombocytopenic Purpura1 trial

Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Terminated· Sanofi logo

Sanofi·Phase 1·NCT00244257·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GMA161. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GMA161 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GMA161. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: Sanofi

GMA161

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thrombocytopenic Purpura1 trial

References

Drug Info

Quick Facts

Related News